This Conrad Notes report on ASCO '98 (American Society of Clinical Oncology) presents succinct analysis of key presentations on cancer treatment, colon cancer and its treatment by CPT-11, colorectal cancer, and other issues in cancer research and cancer care.

• Recurrent Colorectal Cancer (CRC): CPT-11 vs 5-FU Regimens in 267 Patients - E. Van Cutsem
• Preliminary Results on ASCO End-of-Life (EOL) Survey - E.J. Emanuel
• New Tumor-Targeting Methods - L.M. Schuchter
• Prostate Screening Reduces Cancer Deaths - F. Labrie
• CPT-11: Standard Treatment after 5-FU Failure? - D. Cunningham
• Postmenopausal Breast Cancer Risk Reduced by Raloxifene (RAL) - S.R. Cummings
• Chemoprevention of Colorectal Cancer (CRC) - R.N. DuBois
• HER-2 Monoclonal Antibodies Help Chemotherapy in Breast Cancer - D.J. Slamon
• Terminally Ill: End of Life Interests - D.L. Fairclough
• Open Evaluation of CPT-11 in 5-FU-Resistant Colon Cancer - T. Iveson
• Antitumor Activity of 9-CIS Retinoic Acid: AIDS-Related Kaposi's Sarcoma - S.A. Miles
• Negative Alpha Interferon Trial in Colorectal Cancer (CRC) - N. Wolmark

The ASCO '98 Report of Conrad Notes is supported by an unrestricted educational grant from Pharmacia & Upjohn.